PMID- 19619146
OWN - NLM
STAT- MEDLINE
DCOM- 20100929
LR  - 20151119
IS  - 1743-6109 (Electronic)
IS  - 1743-6095 (Linking)
VI  - 6
IP  - 9
DP  - 2009 Sep
TI  - A randomized trial of oral DHEA treatment for sexual function, well-being, and 
      menopausal symptoms in postmenopausal women with low libido.
PG  - 2579-90
LID - 10.1111/j.1743-6109.2009.01381.x [doi]
AB  - INTRODUCTION: Dehydroepiandrosterone (DHEA) and its sulfate DHEAS, which are the 
      most abundant steroids in women, decline with age. We have shown association 
      between low sexual function and low circulating DHEAS levels in women. AIM: The 
      aim of this study was to evaluate whether restoration of circulating DHEA levels 
      in postmenopausal women to the levels seen in young individuals improves sexual 
      function. METHODS: Ninety-three postmenopausal women not using concurrent 
      estrogen therapy were enrolled in a 52-week randomized, double-blind, placebo 
      controlled trial and received either DHEA 50 mg or placebo (PL) daily. MAIN 
      OUTCOME MEASURES: Efficacy was assessed through 26 weeks. The main outcome 
      measures were the change in total satisfying sexual events (SSE) and the change 
      in the Sabbatsberg Sexual Self-Rating Scale (SSS) total score. Secondary measures 
      were the Psychological General Well-Being Questionnaire (PGWB), and the 
      Menopause-Specific Quality of Life Questionnaire (MENQOL). Hormonal levels, 
      adverse events (AEs), serious adverse events (SAEs) and clinical labs were 
      evaluated over 52 weeks. RESULTS: Eighty-five participants (91%) were included in 
      the 26-week efficacy analysis. There were no significant differences between the 
      DHEA and PL groups in the change in total SSE per month or the SSS, PGWB, and 
      MENQOL change scores. Overall AE reports and number of withdrawals as a result of 
      AEs were similar in both groups; however more women in the DHEA group experienced 
      androgenic effects of acne and increased hair growth. CONCLUSIONS: In this study 
      treatment of postmenopausal women with low sexual desire with 50 mg/day DHEA 
      resulted in no significant improvements in sexual function over PL therapy over 
      26 weeks.
FAU - Panjari, Mary
AU  - Panjari M
AD  - NH&MRC Centre of Clinical Research Excellence in the Women's Health Program, 
      Department of Medicine, Central and Eastern Clinical School, Monash University, 
      Alfred Hospital, Prahran, Victoria, Australia. mary.panjari@med.monash.edu.au
FAU - Bell, Robin J
AU  - Bell RJ
FAU - Jane, Fiona
AU  - Jane F
FAU - Wolfe, Rory
AU  - Wolfe R
FAU - Adams, Jenny
AU  - Adams J
FAU - Morrow, Corallee
AU  - Morrow C
FAU - Davis, Susan R
AU  - Davis SR
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20090710
PL  - Netherlands
TA  - J Sex Med
JT  - The journal of sexual medicine
JID - 101230693
RN  - 0 (Adjuvants, Immunologic)
RN  - 459AG36T1B (Dehydroepiandrosterone)
SB  - IM
MH  - Adjuvants, Immunologic/administration & dosage/blood/*therapeutic use
MH  - Administration, Oral
MH  - Adult
MH  - Aged
MH  - Analysis of Variance
MH  - Climacteric/drug effects
MH  - Dehydroepiandrosterone/administration & dosage/blood/*therapeutic use
MH  - Double-Blind Method
MH  - Female
MH  - Health Status Indicators
MH  - Humans
MH  - Linear Models
MH  - *Mental Health
MH  - Middle Aged
MH  - *Patient Satisfaction
MH  - Postmenopause/*drug effects
MH  - Psychometrics
MH  - *Quality of Life
MH  - Risk
MH  - Sexual Dysfunctions, Psychological/*drug therapy/epidemiology
MH  - Surveys and Questionnaires
EDAT- 2009/07/22 09:00
MHDA- 2010/09/30 06:00
CRDT- 2009/07/22 09:00
PHST- 2009/07/22 09:00 [entrez]
PHST- 2009/07/22 09:00 [pubmed]
PHST- 2010/09/30 06:00 [medline]
AID - S1743-6095(15)32656-4 [pii]
AID - 10.1111/j.1743-6109.2009.01381.x [doi]
PST - ppublish
SO  - J Sex Med. 2009 Sep;6(9):2579-90. doi: 10.1111/j.1743-6109.2009.01381.x. Epub 
      2009 Jul 10.